Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Vaccine|April 18, 2015
MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineDuccio Medini, Maria Stella, James Wassil
Vaccine|July 19, 2015
Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adultsTerry Nolan, Miguel O'Ryan, James Wassil, et al.
Therapeutic Advances in Vaccines|January 2, 2015
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionE David McIntosh, Victor Carey, Daniela Toneatto, et al.
Drugs|December 17, 2013
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development programMiguel O'Ryan, Jeffrey Stoddard, Daniela Toneatto, et al.
Environmental Chemistry Letters|October 4, 2021
The impact of human vaccines on bacterial antimicrobial resistance. A reviewKathrin U Jansen, William C Gruber, Raphael Simon, et al.
The Lancet. Infectious Diseases|March 21, 2026
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trialJames Wassil, Jeff Fairman, Carlos A Fierro, et al.
The Lancet. Infectious Diseases|December 7, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trialJames Wassil, Maggie Sisti, Jeff Fairman, et al.
Vaccine|May 9, 2021
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)Jeff Fairman, Paresh Agarwal, Sandrine Barbanel, et al.
Pageof 1